Separate terms with OR to return results that match either term.
 
Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9260 Methotrexate Trexall 50 mg Chemotherapy Antimetabolite Folic Acid Analog No 1953 Jan. 1, 1984 In Use
J3305 Trimetrexate Glucuronate Trimetrexate Glucuronate per 25 mg Chemotherapy Antimetabolite Folic Acid Antagonist No 1993 2007 Jan. 1, 1996 In Use
J9017 Arsenic Trioxide Trisenox 1 mg Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan. 1, 2002 In Use
C9012 Arsenic Trioxide Trisenox unspecified Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan. 1, 2001 Dec. 31, 2001 No Longer Used
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan. 1, 2021 In Use
C9066 Sacituzumab govitecan-hziy Trodelvy 10mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Oct. 1, 2020 Jan. 1, 2021 In Use
Infigratinib Truseltiq Multiple Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2021 In Use
Q5115 Rituximab-abbs Truxima 10mg Immunotherapy Monoclonal Antibody CD20 No 2018 July 1, 2019 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Pexidartinib Turalio Multiple Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Yes 2019 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
Q5111 Pegfilgrastim-cbqv Udenyca 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2019 Jan. 1, 2019 In Use
NA Umbralisib Ukoniq 260.2mg Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Yes 2021 In Use
J3590 Immunotherapy - non specific Unclassified biologics NA Immunotherapy No Jan. 1, 2003 In Use
NA Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 No 2015 In Use
NA Uracil Mustard Uramustine unspecified Chemotherapy Alkylating Agent Nitrogen Mustard No 1962 1999 No Longer Used
J9357 Valrubicin Valstar 200 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1998 Jan. 1, 2000 In Use
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
J9225 Histrelin Acetate Vantas 50 mg Hormonal Therapy GnRH Agonist No 2004 Jan. 1, 2008 In Use
J8670 Rolapitant Varubi 1 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2015 Jan. 1, 2017 In Use
C9235 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan. 1, 2007 Dec. 31, 2007 No Longer Used
J9303 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan. 1, 2008 In Use
Q5129 Bevacizumab-adcd Vegzelma 10mg Immunotherapy Monoclonal Antibody VEGFR No 2023 March 17, 2023 In Use
J9041 Bortezomib Velcade 0.1 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan. 1, 2005 In Use
S0115 Bortezomib Velcade 3.5 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan. 1, 2004 Dec. 31, 2004 No Longer Used

Found 716 results in 2 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.